Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 6 sources
Summary
Deramiocel has been studied as an intravenous treatment administered every three months in outpatient settings, with HOPE-3 participants receiving stable background corticosteroid therapy. The studied population was aged at least ten years and late ambulatory or non-ambulatory. The sponsor’s refined proposed indication focuses on upper limb function. The evidence therefore concerns treatment added to existing care in this trial population; it does not establish an approved treatment position or support replacing corticosteroids or multidisciplinary care.